A Real-World Study About Anemia in Chronic Kidney Disease in China（DASHENG）
DASHENG
An In-Depth Analysis of the Present Diagnostic and Therapeutic Landscape for Renal Anemia in China's Real-World Clinical Environment: A Multicenter Retrospective Cohort Investigation（DASHENG Study）
1 other identifier
observational
20,000
1 country
1
Brief Summary
Anemia affects the quality of life of CKD patients and increases the risk of CKD progression. we conducted a real-world study on patients with anemia in CKD to analyze the disease characteristics and treatment in Chinese patients with CKD-anemia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 10, 2025
CompletedFirst Posted
Study publicly available on registry
August 1, 2025
CompletedStudy Start
First participant enrolled
August 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2027
August 1, 2025
July 1, 2025
1.1 years
July 10, 2025
July 31, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China.
Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China will beperformed to assess the proportions of CKD primary diseases, distribution of CKD stages, baseline Hb level distribution, and proportion of anti-anemia medication usage.
20230101-20241231
Incidence of Adverse Events according to CTCAE 5.0 (Safety profile of different anemia medications in CKD patients with anemia.)
An analysis will be performed to assess the safety according to CTCAE 5.0 .
20230101-20241231
Secondary Outcomes (2)
Analyze the efficacy of different anemia drugs in CKD patients with anemia.
20230101-20241231
Explore the economic burden of anemia in CKD patients
20230101-20241231
Eligibility Criteria
Anemia in Chronic Kidney Disease
You may qualify if:
- diagnosis of CKD (e.g., "%chronic kidney disease%", "%chronic nephropathy%", "%renal failure%", "%nephritis%" for complete ICD-9/10 code mapping\*)
- record of hemodialysis (HD) or peritoneal dialysis (PD) (refer to Attachment 2 for dialysis identification algorithms)
- ≥2 eGFR measurements \<60 mL/min/1.73m² (calculated using CKD-EPI equation) with ≥3-month interval (excluding acute kidney injury)
You may not qualify if:
- Non-renal anemia due to trauma, traffic accidents, major hemorrhage, or other confirmed etiologies (e.g., acute hemorrhagic anemia, nutritional deficiency anemia, hemolytic anemia);
- Diagnosis of acute kidney disease (AKD) without chronic kidney disease (CKD) comorbidity;
- Incomplete critical data elements (including age, sex, or visit dates).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Wei Chenlead
Study Sites (1)
First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 510080, China
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
July 10, 2025
First Posted
August 1, 2025
Study Start
August 1, 2025
Primary Completion (Estimated)
August 31, 2026
Study Completion (Estimated)
August 31, 2027
Last Updated
August 1, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share